Investors might want to bet on Sage Therapeutics, Inc. (SAGE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Sage has launched new capabilities in Sage Intacct to simplify operations and accelerate the close. Today’s finance leaders are under increasing pressure to deliver speed, efficiency, and strategic ...